The ERBB3 receptor in cancer and cancer gene therapy

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Gene Therapy

• Publication date

  2008-04-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/cgt.2008.15PMID 18404164PMCID PMC2761714
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer

  2008cited by this paper
• ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers.

  2008cited by this paper
• ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.

  2008cited by this paper
• Enhancement of erbB2 and erbB3 expression during oral oncogenesis in diabetic rats

  2008cited by this paper
• Structural insights into the transcriptional and translational roles of Ebp1

  2007cited by this paper
• The Asn418-linked N-glycan of ErbB3 plays a crucial role in preventing spontaneous heterodimerization and tumor promotion.

  2007cited by this paper
• The α6β4 Integrin Can Regulate ErbB-3 Expression: Implications for α6β4 Signaling and Function

  2007cited by this paper
• SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.

  2007cited by this paper
• c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function

  2007cited by this paper
• Mapping ErbB receptors on breast cancer cell membranes during signal transduction

  2007cited by this paper
• A novel approach for identification of tumor‐associated antigens expressed on the surface of tumor cells

  2007cited by this paper
• HER3 and mutant EGFR meet MET

  2007cited by this paper
• Activation of Nonreceptor Tyrosine Kinase Bmx/Etk Mediated by Phosphoinositide 3-Kinase, Epidermal Growth Factor Receptor, and ErbB3 in Prostate Cancer Cells*

  2007cited by this paper
• Ebp1-mediated inhibition of cell growth requires serine 363 phosphorylation.

  2007cited by this paper
• Systematic search for the best gene expression markers for melanoma micrometastasis detection

  2007cited by this paper
• Nerve regeneration along bioengineered scaffolds

  2007cited by this paper
• Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3

  2007cited by this paper
• The ErbB4 receptor in fetal rat lung fibroblasts and epithelial type II cells.

  2007cited by this paper
• Modulation of porcine wound repair with a transfected ErbB3 gene and relevant EGF-like ligands.

  2007cited by this paper
• Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

  2007cited by this paper
• Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway

  2007cited by this paper
• A five-gene signature and clinical outcome in non-small-cell lung cancer.

  2007cited by this paper
• Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2.

  2007cited by this paper
• Targeting HER proteins in cancer therapy and the role of the non-target HER3

  2007cited by this paper
• Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis.

  2007cited by this paper
• Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cells

  2007cited by this paper
• Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-kinase/Akt pathway.

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?

  2007cited by this paper
• The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function.

  2007cited by this paper
• Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b*

  2007cited by this paper
• The crystal structure of Ebp1 reveals a methionine aminopeptidase fold as binding platform for multiple interactions

  2007cited by this paper
• Role of heregulin in human cancer

  2007cited by this paper
• Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer

  2007cited by this paper
• Unique Molecular Characteristics of Radiation-Induced Glioblastoma

  2007cited by this paper
• Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer.

  2007cited by this paper
• A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells.

  2007cited by this paper
• HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships.

  2007cited by this paper
• Growth Stimulation of Non–Small Cell Lung Cancer Cell Lines by Antibody against Epidermal Growth Factor Receptor Promoting Formation of ErbB2/ErbB3 Heterodimers

  2007cited by this paper
• The HER family and cancer: emerging molecular mechanisms and therapeutic targets.

  2007cited by this paper
• A Web-based data warehouse on gene expression in human malignant melanoma.

  2007cited by this paper
• Expressions of tumor necrosis factor-converting enzyme and ErbB3 in rats with chronic obstructive pulmonary disease.

  2007cited by this paper
• Ligand-induced structural transitions in ErbB receptor extracellular domains.

  2007cited by this paper
• An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).

  2007cited by this paper
• Bone Microenvironment and Androgen Status Modulate Subcellular Localization of ErbB3 in Prostate Cancer Cells

  2007cited by this paper
• Inhibition of Hsp90: A Multitarget Approach to Radiosensitization

  2007cited by this paper
• Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells

  2006cited by this paper
• Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.

  2006cited by this paper
• Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

  2006cited by this paper
• Essential Role for Rac in Heregulin β1 Mitogenic Signaling: a Mechanism That Involves Epidermal Growth Factor Receptor and Is Independent of ErbB4

  2006cited by this paper
• Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.

  2006cited by this paper
• γ‐Tocotrienol inhibits ErbB3‐dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells

  2006cited by this paper
• A quantitative protein interaction network for the ErbB receptors using protein microarrays

  2006cited by this paper
• Computational modelling of ErbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase activity.

  2006cited by this paper
• Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene.

  2006cited by this paper
• Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor

  2006cited by this paper
• Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features

  2006cited by this paper
• The Mucin Muc4 Potentiates Neuregulin Signaling by Increasing the Cell-surface Populations of ErbB2 and ErbB3*

  2006cited by this paper
• Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells.

  2006cited by this paper
• Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro.

  2006cited by this paper
• ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas

  2006cited by this paper
• Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity

  2006cited by this paper
• Lines

  2006cited by this paper
• Ebp1 isoforms distinctively regulate cell survival and differentiation.

  2006cited by this paper
• Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.

  2006cited by this paper
• ErbB receptor dimerization, localization, and co‐localization in mouse lung type II epithelial cells

  2006cited by this paper
• Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway

  2006cited by this paper
• Epidermal growth factor receptor targeting in cancer.

  2006cited by this paper
• Targeting ADAMS and ERBBs in lung cancer.

  2006cited by this paper
• ErbB receptors: new insights on mechanisms and biology.

  2006cited by this paper
• A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

  2006cited by this paper
• Ebp1 is a dsRNA-binding protein associated with ribosomes that modulates eIF2alpha phosphorylation.

  2006cited by this paper
• Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

  2006cited by this paper
• Molecular determinants of response to RTK‐targeting agents in nonsmall cell lung cancer

  2006cited by this paper
• Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer

  2006cited by this paper
• Expression and Nuclear Localization of ErbB3 in Prostate Cancer

  2006cited by this paper
• Paired Overexpression of ErbB3 and Sox10 in Pilocytic Astrocytoma

  2006cited by this paper
• Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.

  2006cited by this paper
• gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells.

  2006cited by this paper
• EGF–ERBB signalling: towards the systems level

  2006cited by this paper
• Predicting the outcome of chemotherapy for lung cancer.

  2006cited by this paper
• Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease.

  2006cited by this paper
• Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas

  2006cited by this paper
• The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients

  2006cited by this paper
• Signaling through ERBB receptors: multiple layers of diversity and control.

  2006cited by this paper
• Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation

  2006cited by this paper
• A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions

  2006cited by this paper
• An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.

  2006cited by this paper
• The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors

  2006cited by this paper
• Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer

  2006cited by this paper
• Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival

  2006cited by this paper
• ErbB-3 predicts survival in ovarian cancer.

  2006cited by this paper
• Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells

  2006cited by this paper
• Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study

  2006cited by this paper
• The N-terminal Domains of Neuregulin 1 Confer Signal Attenuation*

  2006cited by this paper
• ErbB3-dependent motility and intravasation in breast cancer metastasis.

  2006cited by this paper
• Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis

  2006cited by this paper
• Differentiation of human airway epithelia is dependent on erbB2.

  2006cited by this paper
• The epidermal growth factor family has a dual role in deciding the fate of cancer cells

  2006cited by this paper
• Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.

  2005cited by this paper

• Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan

  2026cites this paper
• The Impact of HER3 Dynamics Altered by HER3-DXd Alone and in Combination with Driver Oncogene Inhibitors on HER3-DXd Efficacy.

  2026cites this paper
• PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma

  2025cites this paper
• PCNP promotes hepatocellular carcinoma progression by upregulating UHRF2 to activate ErbB3/Ras/Raf pathway

  2025cites this paper
• Cooperative multi-view integration with Scalable and Interpretable Model Explainer

  2025cites this paper
• Engineered-affibody conjugates contribute to the specific targeting and cellular retention of polyplexes in Erbb3 overexpressed lung cancer cells.

  2025cites this paper
• Satellite glial cell manipulation prior to axotomy enhances developing dorsal root ganglion central branch regrowth into the spinal cord

  2024cites this paper
• Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review

  2024cites this paper
• Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists

  2024cites this paper
• The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs)

  2024cites this paper
• NUF2 regulated the progression of hepatocellular carcinoma through modulating the PI3K/AKT pathway via stabilizing ERBB3

  2024cites this paper
• Deciphering the Role of ERBB3 Isoforms in Renal Cell Carcinoma: A Comprehensive Genomic and Transcriptomic Analysis

  2024cites this paper
• Updated clinical evidence and molecular features of antibody-drug conjugates for advanced urothelial carcinoma

  2024cites this paper
• MicroRNA-592 Inhibits the Growth of Ovarian Cancer Cells by Targeting ERBB3

  2023cites this paper
• ErbB4 promotes M2 activation of macrophages in idiopathic pulmonary fibrosis

  2023cites this paper
• Peptide G-Protein-Coupled Receptors and ErbB Receptor Tyrosine Kinases in Cancer

  2023cites this paper
• Development and performance evaluations of an HER-2 kit.

  2023cites this paper
• HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple-negative breast cancer metastasis via the inhibition of CXCR4 expression

  2023cites this paper
• ERBB3 mediates the PI3K/AKT/mTOR pathway to alter the epithelial‑mesenchymal transition in cervical cancer and predict immunity filtration outcome

  2023cites this paper
• Downregulation of circ_PLXND1 inhibits tumorigenesis of non‐small cell lung carcinoma via miR‐1287‐5p/ERBB3 axis

  2023cites this paper
• The Signaling of Neuregulin-Epidermal Growth Factor Receptors and Its Impact on the Nervous System

  2023influential citation
• Exploring the Binding Mechanism of NRG1–ERBB3 Complex and Discovery of Potent Natural Products to Reduce Diabetes-Assisted Breast Cancer Progression

  2023cites this paper
• Future potential targets of antibody-drug conjugates in breast cancer.

  2023cites this paper
• Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma.

  2023cites this paper
• HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer

  2023cites this paper
• Uncovering Molecular Mechanisms of Drug Resistance via Network-Constrained Common Structure Identification

  2022cites this paper
• Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis

  2022cites this paper
• Effects of H2O2 Treatment Combined With PI3K Inhibitor and MEK Inhibitor in AGS Cells: Oxidative Stress Outcomes in a Model of Gastric Cancer

  2022cites this paper
• Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3.

  2022cites this paper
• Nucleolar localization of the ErbB3 receptor as a new target in glioblastoma

  2022cites this paper
• SHINE: SubHypergraph Inductive Neural nEtwork

  2022cites this paper
• New emerging targets in advanced urothelial carcinoma: is it the primetime for personalized medicine?

  2022cites this paper
• The molecular, immune features, and risk score construction of intraductal papillary mucinous neoplasm patients

  2022cites this paper
• Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?

  2022cites this paper
• Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1

  2021cites this paper
• Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

  2021cites this paper
• ErbB3 is a critical regulator of cytoskeletal dynamics in brain microvascular endothelial cells: Implications for vascular remodeling and blood brain barrier modulation

  2021cites this paper
• Antibody–drug conjugates in solid tumors: a look into novel targets

  2021cites this paper
• Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders.

  2021influential citation
• Antibody–Drug Conjugates for the Treatment of Breast Cancer

  2021cites this paper
• Hepatic Proteomics Analysis of Nonalcoholic Fatty Liver Disease Obese Rat Model After Short- and Long-Term Soy Protein Isolate Feeding

  2021cites this paper
• Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer

  2021cites this paper
• Making ERRFI1-Derived Peptides ‘Bindable’ to the Allosteric Dimerization Interface of Breast Cancer ERBB3 Kinase by Adding a Nonbonded Interaction System

  2021cites this paper
• Exome Sequencing in BRCA1-2 Candidate Familias: The Contribution of Other Cancer Susceptibility Genes

  2021cites this paper
• Neuregulin Signaling in the Tumor Microenvironment.

  2021cites this paper
• Molecular changes in EGFR downstream signalling and intracellular calcium changes associated with the cisplatin-resistant phenotype of lung cancer cells

  2020cites this paper
• Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines

  2020cites this paper
• The biology and rationale of targeting nectin-4 in urothelial carcinoma

  2020cites this paper
• New insights into ErbB3 function and therapeutic targeting in cancer

  2020cites this paper
• Identification of potential biomarkers associated with pathogenesis of primary prostate cancer based on meta-analysis approaches

  2020cites this paper
• Rewiring ERBB3 and ERK signaling confers resistance to FGFR1 inhibition in gastrointestinal cancer harbored an ERBB3-E928G mutation

  2020cites this paper
• Analysis of expression of candidate genes for polycystic ovary syndrome in adult and fetal human and fetal bovine ovaries†

  2020cites this paper
• Spotlight on the Granules (Grainyhead-Like Proteins) – From an Evolutionary Conserved Controller of Epithelial Trait to Pioneering the Chromatin Landscape

  2020cites this paper
• Circular RNA in Lung Cancer Research: Biogenesis, Functions, and Roles

  2020cites this paper
• The many substrates and functions of NEDD4-1

  2019cites this paper
• 3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development.

  2019cites this paper
• Biallelic ERBB3 loss-of-function variants are associated with a novel multisystem syndrome without congenital contracture

  2019cites this paper
• MicroRNA-335 inhibits proliferation , invasion , and migration of breast cancer cells possibly via ERBB 3

  2019cites this paper
• Mechanisms of ERBB3 Action in Human Neoplasia.

  2019cites this paper
• ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics

  2019influential citation
• Bio-assay: The best alternative for conventional methods in detection of epidermal growth factor.

  2019cites this paper
• Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis

  2019cites this paper
• Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer

  2019cites this paper
• Telmisartan Inhibits Cell Proliferation and Tumor Growth of Esophageal Squamous Cell Carcinoma by Inducing S-Phase Arrest In Vitro and In Vivo

  2019cites this paper
• EBP1 nuclear accumulation negatively feeds back on FERONIA-mediated RALF1 signaling

  2018cites this paper
• Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients

  2018cites this paper
• The role of ErbB3 binding protein 1 in cancer: Friend or foe?

  2018cites this paper
• Targeted Next-Generation Sequencing Identifies Actionable Targets in Estrogen Receptor Positive and Estrogen Receptor Negative Endometriod Endometrial Cancer

  2018cites this paper
• Evaluation of Protein Levels of the Receptor Tyrosine Kinase ErbB3 in Serum.

  2018cites this paper
• Experimental and investigational drugs for the treatment of anal cancer

  2018cites this paper
• Quantitative super-resolution single molecule microscopy dataset of YFP-tagged growth factor receptors

  2018influential citation
• Transfer-RNA-mediated enhancement of ribosomal proteins S6 kinases signaling for cell proliferation

  2018cites this paper
• Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.

  2018cites this paper
• Increased circular RNA hsa_circ_0012673 acts as a sponge of miR-22 to promote lung adenocarcinoma proliferation.

  2018cites this paper
• Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7

  2018cites this paper
• HER-3 Knocking Down Induces G2/M Arrest in Gastric Cancer Cells

  2018influential citation
• Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients

  2018cites this paper
• Prediction of Colorectal Cancer Driver Genes from Patients’ Genome Data

  2018cites this paper
• Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer

  2017cites this paper
• Assessment of Specificity of an Adenovirus Targeted to HER3/4.

  2017cites this paper
• Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S-1 chemotherapy.

  2017cites this paper
• Discovery of pancreatic cancer biomarker(s) using focused pathway analyses

  2017cites this paper
• Pseudokinases: update on their functions and evaluation as new drug targets.

  2017cites this paper
• Nectin-like molecule-4/cell adhesion molecule 4 inhibits the ligand-induced dimerization of ErbB3 with ErbB2

  2017cites this paper
• 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors

  2017cites this paper
• ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)

  2017cites this paper
• Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients

  2017cites this paper
• HER3 as a Therapeutic Target in Cancer

  2017cites this paper
• The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors.

  2017cites this paper
• Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

  2017cites this paper
• Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

  2017cites this paper
• NRG1-ErbB Lost in Translation: A New Paradigm for Lung Cancer?

  2017cites this paper
• 6.01 – Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R

  2017cites this paper
• Disease-associated glycans on cell surface proteins.

  2016cites this paper
• The role of the epidermal growth factor receptor family in prostate cancer and their potential as therapeutic targets

  2016influential citation
• HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis

  2016cites this paper
• N-glycans of growth factor receptors: their role in receptor function and disease implications.

  2016cites this paper
• Characterization and Applications of Single-Domain Antibody Mimics against ErbB 3

  2016cites this paper
• Hepatitis B virus X protein reduces the stability of Nrdp1 to up-regulate ErbB3 in hepatocellular carcinoma cells

  2016cites this paper
• Endocytic downregulation of the oncoproteins ErbB2 and ErbB3

  2016influential citation